DK3717636T3 - Adeno-associeret-virus-variantcapsider og anvendelse til inhibering af angiogenese - Google Patents
Adeno-associeret-virus-variantcapsider og anvendelse til inhibering af angiogenese Download PDFInfo
- Publication number
- DK3717636T3 DK3717636T3 DK18881166.5T DK18881166T DK3717636T3 DK 3717636 T3 DK3717636 T3 DK 3717636T3 DK 18881166 T DK18881166 T DK 18881166T DK 3717636 T3 DK3717636 T3 DK 3717636T3
- Authority
- DK
- Denmark
- Prior art keywords
- adeno
- inhibiting angiogenesis
- virus variant
- variant capsids
- capsids
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14145—Special targeting system for viral vectors
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762590976P | 2017-11-27 | 2017-11-27 | |
US201862664726P | 2018-04-30 | 2018-04-30 | |
PCT/US2018/062478 WO2019104279A1 (en) | 2017-11-27 | 2018-11-26 | Adeno-associated virus variant capsids and use for inhibiting angiogenesis |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3717636T3 true DK3717636T3 (da) | 2023-05-30 |
Family
ID=66631726
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK18881166.5T DK3717636T3 (da) | 2017-11-27 | 2018-11-26 | Adeno-associeret-virus-variantcapsider og anvendelse til inhibering af angiogenese |
Country Status (21)
Country | Link |
---|---|
US (1) | US11766489B2 (da) |
EP (3) | EP4272728A2 (da) |
JP (3) | JP7184894B2 (da) |
KR (1) | KR20200088853A (da) |
CN (1) | CN111770999A (da) |
AU (2) | AU2018372235B9 (da) |
BR (1) | BR112020010674A2 (da) |
CA (1) | CA3083472A1 (da) |
CL (1) | CL2020001360A1 (da) |
CR (1) | CR20200282A (da) |
DK (1) | DK3717636T3 (da) |
ES (1) | ES2946747T3 (da) |
FI (1) | FI3717636T3 (da) |
IL (1) | IL274712A (da) |
MX (1) | MX2020005451A (da) |
PE (1) | PE20210915A1 (da) |
PH (1) | PH12020550706A1 (da) |
PT (1) | PT3717636T (da) |
SG (1) | SG11202004545XA (da) |
UA (1) | UA127831C2 (da) |
WO (1) | WO2019104279A1 (da) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
RU2744860C2 (ru) | 2015-12-30 | 2021-03-16 | Кодиак Сайенсиз Инк. | Антитела и их конъюгаты |
CA3086045A1 (en) * | 2017-12-19 | 2019-06-27 | Akouos, Inc. | Aav-mediated delivery of therapeutic antibodies to the inner ear |
WO2020068990A1 (en) | 2018-09-26 | 2020-04-02 | California Institute Of Technology | Adeno-associated virus compositions for targeted gene therapy |
WO2021050614A2 (en) * | 2019-09-09 | 2021-03-18 | Massachusetts Eye And Ear Infirmary | Methods and compositions for modulating the interaction between adeno-associated virus (aav) and the aav receptor (aavr) for altered bio-distribution of aav |
US20220411508A1 (en) * | 2019-09-09 | 2022-12-29 | The Regents Of The University Of California | Compositions and methods for making and using multispecific antibodies |
CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
CA3157464A1 (en) * | 2019-10-31 | 2021-05-06 | Universitat Bern | Aav vector variants for ocular gene delivery |
US20240067678A1 (en) * | 2020-12-16 | 2024-02-29 | Children's Medical Research Institute | Adeno-associated virus capsids and vectors |
AU2021399882A1 (en) * | 2020-12-16 | 2023-07-06 | Children's Medical Research Institute | Aav capsids and vectors |
CN113041360A (zh) * | 2021-04-01 | 2021-06-29 | 深圳廷美奥生物技术有限公司 | 一种用于治疗年龄相关性黄斑变性的药物 |
JP2024516128A (ja) * | 2021-04-09 | 2024-04-12 | アビラマックス・バイオファーマ・インコーポレイテッド | 眼での導入遺伝子発現のための組成物および方法 |
EP4326339A2 (en) | 2021-04-20 | 2024-02-28 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Compositions and methods for treating retinal degenerative disorders |
KR20240014477A (ko) * | 2021-05-28 | 2024-02-01 | 상하이 레제네리드 테라피즈 컴퍼니 리미티드 | 변이체 캡시드를 갖는 재조합 아데노-연관 바이러스 및 이의 응용 |
CN113481237A (zh) * | 2021-06-29 | 2021-10-08 | 厦门朔望医药科技有限公司 | 一种预防和治疗新生血管眼部疾病的基因药物 |
CA3231028A1 (en) * | 2021-09-06 | 2023-03-09 | Shaoran Wang | Treatment of rpe65-associated eye diseases and disorders |
CN114057840B (zh) * | 2021-10-14 | 2022-09-20 | 和元生物技术(上海)股份有限公司 | 包含变异的aav9衣壳蛋白的重组腺相关病毒颗粒 |
WO2023089151A1 (en) * | 2021-11-19 | 2023-05-25 | The University Of Bristol | Materials and methods for treatment of macular degeneration |
CN116444626A (zh) * | 2021-12-28 | 2023-07-18 | 成都弘基生物科技有限公司 | 经过修饰的aav衣壳蛋白及其用途 |
WO2023173086A1 (en) * | 2022-03-11 | 2023-09-14 | Avirmax Biopharma Inc. | Compositions and methods for expressing therapeutics |
WO2023236964A1 (zh) * | 2022-06-07 | 2023-12-14 | 成都弘基生物科技有限公司 | 腺相关病毒药物组合物及其用途 |
CN117304256B (zh) * | 2022-12-08 | 2024-04-16 | 广州派真生物技术有限公司 | 腺相关病毒突变体及其应用 |
CN117247434B (zh) * | 2023-11-10 | 2024-02-02 | 上海朗昇生物科技有限公司 | 衣壳修饰型病毒载体及其制备和用途 |
Family Cites Families (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US608200A (en) | 1898-08-02 | Toy cannon | ||
US20030215422A1 (en) | 1996-09-11 | 2003-11-20 | John A. Chiorini | Aav4 vector and uses thereof |
US6156303A (en) | 1997-06-11 | 2000-12-05 | University Of Washington | Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom |
US7323179B2 (en) | 1997-12-19 | 2008-01-29 | Naomi Balaban | Methods and compositions for the treatment and prevention of Staphylococcus and other bacterial infections |
US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
WO1999061601A2 (en) | 1998-05-28 | 1999-12-02 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Aav5 vector and uses thereof |
US6984517B1 (en) | 1998-05-28 | 2006-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | AAV5 vector and uses thereof |
US6759237B1 (en) | 1998-11-05 | 2004-07-06 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same |
DE69936104T2 (de) | 1998-11-05 | 2008-01-17 | The Trustees Of The University Of Pennsylvania | Nukleinsäuresequenzen des adeno-assoziierten virus des serotyps i, und vektoren und wirtszellen, die diese enthalten |
AU780231B2 (en) | 1998-11-10 | 2005-03-10 | University Of North Carolina At Chapel Hill, The | Virus vectors and methods of making and administering the same |
DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
IL146890A0 (en) | 1999-06-08 | 2002-08-14 | Regeneron Pharma | Modified chimeric polypeptides with improved pharmacokinetic properties |
WO2001029058A1 (en) | 1999-10-15 | 2001-04-26 | University Of Massachusetts | Rna interference pathway genes as tools for targeted genetic interference |
WO2001075164A2 (en) | 2000-03-30 | 2001-10-11 | Whitehead Institute For Biomedical Research | Rna sequence-specific mediators of rna interference |
EP1289368B1 (en) | 2000-05-23 | 2010-01-06 | University of Rochester | Method of producing herpes simplex virus amplicons, resulting amplicons, and their use |
US20100305186A1 (en) | 2000-05-30 | 2010-12-02 | Johnson & Johnson Research Pty Limited | Methods for mediating gene suppression |
CA2456008A1 (en) | 2000-08-19 | 2002-02-28 | Axordia Limited | Stem cell differentiation |
WO2002029858A2 (en) | 2000-09-29 | 2002-04-11 | Infineon Technologies North America Corp. | Deep trench etching method to reduce/eliminate formation of black silicon |
WO2002061090A2 (en) | 2000-12-14 | 2002-08-08 | Genentech, Inc. | Prokaryotically produced antibodies and uses thereof |
US7749492B2 (en) | 2001-01-05 | 2010-07-06 | Nationwide Children's Hospital, Inc. | AAV vectors and methods |
AU2002248297A1 (en) | 2001-01-05 | 2002-07-16 | Children's Hospital, Inc. | Aav2 vectors and methods |
CA2467959C (en) | 2001-11-09 | 2009-03-10 | Robert M. Kotin | Production of adeno-associated virus in insect cells |
ES2258601T3 (es) | 2001-11-13 | 2006-09-01 | The Trustees Of The University Of Pennsylvania | Un metodo para la identificacion de las secuencias desconocidas del virus adeno-asociado (vaa) y un kit para el metodo. |
EP2573170B1 (en) | 2001-12-17 | 2017-12-20 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (AAV) serotype 9 sequences, vectors containing same, and uses therefor |
EP3517134B1 (en) | 2001-12-17 | 2024-01-17 | The Trustees of the University of Pennsylvania | Adeno-associated virus (aav) serotype 8 sequences, vectors containing same and uses therefor |
EP1456383B1 (en) | 2001-12-21 | 2014-03-12 | Medigene AG | A library of modified structural genes or capsid modified particles useful for the identification of viral clones with desired cell tropism |
AU2003253595A1 (en) | 2002-04-05 | 2003-11-03 | The Children's Hospital Of Philadelphia | Methods for the production of chimeric adeno-associated virus (aav) vectors, compositions of chimeric aav vectors, and methods of use thereof |
AU2003221733A1 (en) | 2002-04-17 | 2003-11-03 | University Of Florida Research Foundation, Inc. | Improved raav vectors |
NZ561656A (en) | 2002-05-01 | 2009-03-31 | Univ Florida | Improved rAAV expression systems for genetic modification of specific capsid proteins |
US20040023390A1 (en) | 2002-08-05 | 2004-02-05 | Davidson Beverly L. | SiRNA-mediated gene silencing with viral vectors |
WO2004020600A2 (en) | 2002-08-28 | 2004-03-11 | University Of Florida | Modified aav |
US7186522B2 (en) | 2003-03-31 | 2007-03-06 | Cytyc Corporation | Papanicolau staining process |
US20060286545A1 (en) | 2003-05-23 | 2006-12-21 | Mount Sinai School Of Medicine Of New York University | Viral vectors with improved properties |
EP1486567A1 (en) | 2003-06-11 | 2004-12-15 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Improved adeno-associated virus (AAV) vector for gene therapy |
US8071028B2 (en) | 2003-06-12 | 2011-12-06 | Abbott Diabetes Care Inc. | Method and apparatus for providing power management in data communication systems |
ES2629380T3 (es) | 2003-06-19 | 2017-08-09 | Genzyme Corporation | Viriones de AAV con inmunorreactividad reducida y usos de los mismos |
US9233131B2 (en) | 2003-06-30 | 2016-01-12 | The Regents Of The University Of California | Mutant adeno-associated virus virions and methods of use thereof |
US9441244B2 (en) | 2003-06-30 | 2016-09-13 | The Regents Of The University Of California | Mutant adeno-associated virus virions and methods of use thereof |
CN1856576B (zh) | 2003-09-30 | 2011-05-04 | 宾夕法尼亚州立大学托管会 | 腺伴随病毒(aav)进化支、序列、含有这些序列的载体及它们的应用 |
PL1791858T3 (pl) | 2004-09-24 | 2010-09-30 | Intercell Ag | Zmodyfikowane białko kapsydowe VP1 z parwowirusa B19 |
CN101124328A (zh) | 2004-12-15 | 2008-02-13 | 北卡罗来纳查佩尔山大学 | 嵌合载体 |
EP2359865B1 (en) | 2005-04-07 | 2013-10-02 | The Trustees of The University of Pennsylvania | Method of increasing the function of an AAV vector |
WO2006119432A2 (en) | 2005-04-29 | 2006-11-09 | The Government Of The U.S.A., As Rep. By The Sec., Dept. Of Health & Human Services | Isolation, cloning and characterization of new adeno-associated virus (aav) serotypes |
WO2007046703A2 (en) | 2005-10-20 | 2007-04-26 | Amsterdam Molecular Therapeutics B.V. | Improved aav vectors produced in insect cells |
US7867484B2 (en) | 2006-01-27 | 2011-01-11 | University Of North Carolina At Chapel Hill | Heparin and heparan sulfate binding chimeric vectors |
EP2007795B1 (en) | 2006-03-30 | 2016-11-16 | The Board Of Trustees Of The Leland Stanford Junior University | Aav capsid proteins |
WO2008027084A2 (en) | 2006-04-28 | 2008-03-06 | The Trustees Of The University Of Pennsylvania | Modified aav vectors having reduced capsid immunogenicity and use thereof |
US20070274985A1 (en) * | 2006-05-26 | 2007-11-29 | Stefan Dubel | Antibody |
WO2008124015A1 (en) | 2007-04-09 | 2008-10-16 | The Regents Of The University Of California | Methods for purifying adeno-associated virus virions |
EP3492596A1 (en) | 2007-04-09 | 2019-06-05 | University of Florida Research Foundation, Inc. | Raav vector compositions having tyrosine-modified capsid proteins and methods for use |
EP2012122A1 (en) | 2007-07-06 | 2009-01-07 | Medigene AG | Mutated parvovirus structural proteins as vaccines |
ES2602610T3 (es) | 2007-05-31 | 2017-02-21 | Medigene Ag | Proteína estructural mutada de un parvovirus |
US8299215B2 (en) | 2007-07-14 | 2012-10-30 | University Of Iowa Research Foundation | Methods and compositions for treating brain diseases |
WO2009108274A2 (en) | 2008-02-26 | 2009-09-03 | The University Of North Carolina At Chapel Hill | Methods and compositions for adeno-associated virus (aav) with hi loop mutations |
WO2009137006A2 (en) | 2008-04-30 | 2009-11-12 | The University Of North Carolina At Chapel Hill | Directed evolution and in vivo panning of virus vectors |
EP2297185A1 (en) | 2008-06-17 | 2011-03-23 | Amsterdam Molecular Therapeutics (AMT) B.V. | Parvoviral capsid with incorporated gly-ala repeat region |
JP2010002479A (ja) | 2008-06-18 | 2010-01-07 | Crossfor:Kk | メガネレンズ用装飾体およびメガネ用装飾体装着具 |
CN110372792A (zh) | 2008-06-25 | 2019-10-25 | 艾斯巴技术-诺华有限责任公司 | 抑制vegf的稳定和可溶的抗体 |
WO2010031865A1 (en) | 2008-09-19 | 2010-03-25 | Charitē Universitätsmedizin Berlin | Identification and characterisation of recombinant viral gene therapy vectors |
US8889641B2 (en) | 2009-02-11 | 2014-11-18 | The University Of North Carolina At Chapel Hill | Modified virus vectors and methods of making and using the same |
WO2010138263A2 (en) | 2009-05-28 | 2010-12-02 | University Of Massachusetts | Novel aav 's and uses thereof |
WO2010141706A1 (en) | 2009-06-03 | 2010-12-09 | Cedars-Sinai Medical Center | Effective vector platform for gene transfer and gene therapy |
WO2011038187A1 (en) | 2009-09-25 | 2011-03-31 | The Trustees Of The University Of Pennsylvania | Controlled adeno-associated virus (aav) diversification and libraries prepared therefrom |
US8299295B2 (en) | 2009-10-15 | 2012-10-30 | Johnson Matthey Public Limited Company | Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs |
US8263396B2 (en) | 2010-04-01 | 2012-09-11 | Weidong Xiao | Methods and compositions for the production of recombinant virus vectors |
WO2011133890A1 (en) | 2010-04-23 | 2011-10-27 | University Of Massachusetts | Cns targeting aav vectors and methods of use thereof |
US8628966B2 (en) | 2010-04-30 | 2014-01-14 | City Of Hope | CD34-derived recombinant adeno-associated vectors for stem cell transduction and systemic therapeutic gene transfer |
US8927514B2 (en) | 2010-04-30 | 2015-01-06 | City Of Hope | Recombinant adeno-associated vectors for targeted treatment |
CA2798988C (en) | 2010-05-17 | 2020-03-10 | Sangamo Biosciences, Inc. | Tal-effector (tale) dna-binding polypeptides and uses thereof |
US8663624B2 (en) | 2010-10-06 | 2014-03-04 | The Regents Of The University Of California | Adeno-associated virus virions with variant capsid and methods of use thereof |
US10415056B2 (en) | 2010-11-10 | 2019-09-17 | Fred Hutchinson Cancer Research Center | Compositions and methods for generating adeno-associated viral vectors with undetectable capsid gene contamination |
DK2673289T3 (da) | 2011-02-10 | 2023-07-24 | Univ North Carolina Chapel Hill | Virusvektorer med modificerede transduktionsprofiler og fremgangsmåder til fremstilling og anvendelse deraf |
EP2675484B1 (en) | 2011-02-14 | 2018-05-30 | The Children's Hospital of Philadelphia | Improved aav8 vector with enhanced functional activity and methods of use thereof |
EP2675902B1 (en) | 2011-02-17 | 2019-03-27 | The Trustees Of The University Of Pennsylvania | Compositions and methods for altering tissue specificity and improving aav9-mediated gene transfer |
CA2833870C (en) | 2011-04-22 | 2020-03-10 | The Regents Of The University Of California | Adeno-associated virus virions with variant capsid and methods of use thereof |
KR101397088B1 (ko) | 2011-06-10 | 2014-05-19 | 강원대학교산학협력단 | 암세포 증식 억제와 혈관신생 억제를 위한 융합 단백질 및 이를 포함한 항암 조성물 |
WO2012169822A2 (ko) * | 2011-06-10 | 2012-12-13 | 강원대학교산학협력단 | 암세포 증식 억제와 혈관신생 억제를 위한 융합 단백질 및 이를 포함한 항암 조성물 |
CN103748114B (zh) | 2011-08-23 | 2017-07-21 | 罗切格利卡特公司 | T细胞活化性双特异性抗原结合分子 |
EP3795581A3 (en) | 2011-08-24 | 2021-06-09 | The Board of Trustees of the Leland Stanford Junior University | New avv capsid proteins for nucleic acid transfer |
WO2013057235A1 (en) | 2011-10-21 | 2013-04-25 | Intervet International B.V. | Recombinant nonpathogenic mdv vector providing multivalent immunity |
WO2013096955A1 (en) | 2011-12-23 | 2013-06-27 | Case Western Reserve University | Targeted gene modification using hybrid recombinant adeno-associated virus |
AU2013221212B2 (en) | 2012-02-17 | 2018-08-09 | The Children's Hospital Of Philadelphia | AAV vector compositions and methods for gene transfer to cells, organs and tissues |
HUE054087T2 (hu) | 2012-04-18 | 2021-09-28 | Childrens Hospital Philadelphia | Készítmények és eljárások nagy hatékonyságú géntranszferre AAV kapszidvariánsok alkalmazásával |
US20140162319A2 (en) | 2012-05-02 | 2014-06-12 | Sangeetha Hareendran | Nucleotide sequences, methods, kit and a recombinant cell thereof |
EP2847337A4 (en) | 2012-05-09 | 2016-04-27 | Univ Oregon Health & Science | PLASMIDS AND VIRAL VECTORS ASSOCIATED WITH ADENOVIRUS |
WO2013174760A1 (en) | 2012-05-25 | 2013-11-28 | Deutsches Krebsforschungszentrum | Optimized aav-vectors for high transduction rates in dendritic cells |
EP2692731A1 (en) | 2012-07-31 | 2014-02-05 | Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe | Recombinant Adeno-Associated virus (AAV) vector particles displaying high-affinity ligands for cell-type specific gene delivery |
AU2013323270B2 (en) | 2012-09-28 | 2017-09-28 | The University Of North Carolina At Chapel Hill | AAV vectors targeted to oligodendrocytes |
US9938541B2 (en) | 2012-12-25 | 2018-04-10 | Takara Bio Inc. | AAV variant |
DK2954051T3 (da) | 2013-02-08 | 2019-07-08 | Univ Pennsylvania | Modificeret kapsid til genoverførsel til behandling af nethinden |
AU2014244167A1 (en) | 2013-03-13 | 2015-10-08 | The Children's Hospital Of Philadelphia | Adeno-associated virus vectors and methods of use thereof |
CA2907799A1 (en) | 2013-05-31 | 2014-12-04 | The Regents Of The University Of California | Adeno-associated virus variants and methods of use thereof |
US11197937B2 (en) * | 2016-04-15 | 2021-12-14 | The Trustees Of The University Of Pennsylvania | Compositions for treatment of wet age-related macular degeneration |
EP3448427A1 (en) | 2016-04-29 | 2019-03-06 | CureVac AG | Rna encoding an antibody |
RU2725286C2 (ru) * | 2016-05-13 | 2020-06-30 | 4Д Молекьюлар Терапьютикс Инк. | Варианты капсидов аденоассоциированного вируса и способы их применения |
WO2017218974A2 (en) * | 2016-06-16 | 2017-12-21 | Adverum Biotechnologies, Inc. | Treatment of amd using aav2 variant with aflibercept |
NZ763018A (en) | 2017-09-20 | 2023-02-24 | 4D Molecular Therapeutics Inc | Adeno-associated virus variant capsids and methods of use thereof |
MX2020003945A (es) * | 2017-10-18 | 2020-11-09 | Regenxbio Inc | Tratamiento de enfermedades oculares y cancer de colon metastasico con vegf-trap humano modificado post-traduccionalmente . |
-
2018
- 2018-11-26 FI FIEP18881166.5T patent/FI3717636T3/fi active
- 2018-11-26 CN CN201880087687.3A patent/CN111770999A/zh active Pending
- 2018-11-26 UA UAA202003841A patent/UA127831C2/uk unknown
- 2018-11-26 EP EP23186524.7A patent/EP4272728A2/en active Pending
- 2018-11-26 KR KR1020207017143A patent/KR20200088853A/ko not_active Application Discontinuation
- 2018-11-26 CA CA3083472A patent/CA3083472A1/en active Pending
- 2018-11-26 EP EP23152950.4A patent/EP4219695A3/en active Pending
- 2018-11-26 PT PT188811665T patent/PT3717636T/pt unknown
- 2018-11-26 MX MX2020005451A patent/MX2020005451A/es unknown
- 2018-11-26 AU AU2018372235A patent/AU2018372235B9/en active Active
- 2018-11-26 JP JP2020528888A patent/JP7184894B2/ja active Active
- 2018-11-26 EP EP18881166.5A patent/EP3717636B1/en active Active
- 2018-11-26 ES ES18881166T patent/ES2946747T3/es active Active
- 2018-11-26 SG SG11202004545XA patent/SG11202004545XA/en unknown
- 2018-11-26 DK DK18881166.5T patent/DK3717636T3/da active
- 2018-11-26 US US16/765,758 patent/US11766489B2/en active Active
- 2018-11-26 PE PE2020000575A patent/PE20210915A1/es unknown
- 2018-11-26 BR BR112020010674-7A patent/BR112020010674A2/pt unknown
- 2018-11-26 WO PCT/US2018/062478 patent/WO2019104279A1/en unknown
- 2018-11-26 CR CR20200282A patent/CR20200282A/es unknown
-
2020
- 2020-05-17 IL IL274712A patent/IL274712A/en unknown
- 2020-05-22 CL CL2020001360A patent/CL2020001360A1/es unknown
- 2020-05-26 PH PH12020550706A patent/PH12020550706A1/en unknown
-
2022
- 2022-05-23 AU AU2022203494A patent/AU2022203494A1/en active Pending
- 2022-06-24 JP JP2022101767A patent/JP2022121534A/ja active Pending
-
2023
- 2023-12-05 JP JP2023205214A patent/JP2024015194A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3717636T3 (da) | Adeno-associeret-virus-variantcapsider og anvendelse til inhibering af angiogenese | |
DK3303379T3 (da) | Tigit-bindende midler og anvendelser deraf | |
DK3448386T3 (da) | Isoquinolin-3-ylcarboxamider og fremstilling og anvendelse deraf | |
DK3610005T3 (da) | Peptidligase og anvendelse deraf | |
CR20180278A (es) | Enlazadores de pd1 y/o lag3 | |
DK3365368T3 (da) | Tgfbeta1-bindende immunoglobuliner og anvendelse deraf | |
DK3368534T3 (da) | Valbenazin-ditosylat og polymorfer deraf | |
DK3310371T3 (da) | Glucagon og GLP-1-Co-agonistforbindelser | |
DK3412302T3 (da) | Modificerede fgf-21-polypeptider og anvendelser deraf | |
DK3253875T3 (da) | Tau-antisense-oligomerer og anvendelser deraf | |
DK3452463T3 (da) | Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf | |
DK3380101T3 (da) | Eif4-a-inhiberende forbindelser og fremgangsmåder relateret dertil | |
DK3357513T3 (da) | Farmaceutisk sammensætning og anvendelse deraf | |
DK3319611T3 (da) | Oxysteroler og fremgangsmåder til anvendelse deraf | |
DK3018183T3 (da) | Halogenolefinbaseret sammensætning og anvendelse deraf | |
DK3218358T3 (da) | Ifluorometyl-aminopyridiner og difluorometyl-aminopyrimidiner | |
DK3227237T3 (da) | Indretning og anvendelse deraf til uv-bearbejdning af fluider | |
DK3193611T3 (da) | Mk2-inhibitorer og anvendelser deraf | |
DK3265641T3 (da) | Stigørenhed og fremgangsmåde | |
DK3621694T3 (da) | Lrrc33-inhibitorer og anvendelse heraf | |
DK3161139T3 (da) | Tlr-4-specifikke aptamerer og anvendelser heraf | |
DK3290441T3 (da) | Rgma-bindingsprotein og anvendelse deraf | |
DK3325618T3 (da) | Hidtil ukendte trypsin-isoformer og anvendelse deraf | |
DK3128005T3 (da) | Sirp-alfa-variantkonstruktioner og anvendelser deraf | |
DK3256479T3 (da) | 4-substituerede benzoxaborolforbindelser og anvendelser deraf |